Top

CNS Drugs

Published in:

01-06-2002 | Adis Spotlight

Spotlight on Paroxetine in Psychiatric Disorders in Adults

Authors: Antona J. Wagstaff, Susan M. Cheer, Anna J. Matheson, Douglas Ormrod, Karen L. Goa

Published in: CNS Drugs | Issue 6/2002

Abstract

Paroxetine is a selective serotonin reuptake inhibitor (SSRI), with antidepres-sant and anxiolytic activity.

In 6- to 24-week well designed trials, oral paroxetine 10 to 50 mg/day was significantly more effective than placebo, at least as effective as tricyclic anti-depressants (TCAs) and as effective as other SSRIs and other antidepressants in the treatment of major depressive disorder. Relapse or recurrence over 1 year after the initial response was significantly lower with paroxetine 10 to 50 mg/day than with placebo and similar to that with imipramine 50 to 275 mg/day.

The efficacy of paroxetine 10 to 40 mg/day was similar to that of TCAs and fluoxetine 20 to 60 mg/day in 6- to 12-week trials in patients aged ≥60 years with major depression. Paroxetine 10 to 40 mg/day improved depressive symptoms to an extent similar to that of TCAs in patients with comorbid illness, and was more effective than placebo in the treatment of dysthymia and minor depression.

Paroxetine 20 to 60 mg/day was more effective than placebo after 8 to 12 weeks’ treatment of obsessive-compulsive disorder (OCD), panic disorder, social anxiety disorder (social phobia), generalised anxiety disorder (GAD) and post-traumatic stress disorder (PTSD). Improvement was maintained or relapse was prevented for 24 weeks to 1 year in patients with OCD, panic disorder, social anxiety disorder or GAD. The efficacy of paroxetine was similar to that of other SSRIs in patients with OCD and panic disorder and similar to that of imipramine but greater than that of 2′chlordesmethyldiazepam in patients with GAD.

Paroxetine is generally well tolerated in adults, elderly individuals and patients with comorbid illness, with a tolerability profile similar to that of other SSRIs. The most common adverse events with paroxetine were nausea, sexual dysfunction, somnolence, asthenia, headache, constipation, dizziness, sweating, tremor and decreased appetite.

In conclusion, paroxetine, in common with other SSRIs, is generally better tolerated than TCAs and is a first-line treatment option for major depressive disorder, dysthymia or minor depression. Like other SSRIs, paroxetine is also an appropriate first-line therapy for OCD, panic disorder, social anxiety disorder, GAD and PTSD. Notably, paroxetine is the only SSRI currently approved for the treatment of social anxiety disorder and GAD, which makes it the only drug of its class indicated for all five anxiety disorders in addition to major depressive disorder. Thus, given the high degree of psychiatric comorbidity of depression and anxiety, paroxetine is an important first-line option for the treatment of major depressive disorder, OCD, panic disorder, social anxiety disorder, GAD and PTSD.

Gunasekara NS, Noble S, Benfield P. Paroxetine: an update of its pharmacology and therapeutic use in depression and a review of its use in other disorders. Drugs 1998; 55(1): 85–120PubMedCrossRef

Owens MJ, Knight DL. Human monoamine transporter binding profile of the SSRIs. American Psychiatric Association 2000 Annual Meeting. The Doctor-Patient Relationship: New Research Abstracts; 2000 May 13; Chicago, 144-5

Schlösser R, Röschke J, Rossbach W, et al. Conventional and spectral power analysis of all-night sleep EEG after subchronic treatment with paroxetine in healthy male volunteers. Eur Neuropsychopharmacol 1998; 8: 273–8PubMedCrossRef

Prakash A, Foster RH. Paroxetine: a review of its use in social anxiety disorder. CNS Drugs 1999; 12: 151–69CrossRef

Sharpley AL, Williamson DJ, Attenburrow MEJ, et al. The effects of paroxetine and nefazodone on sleep: a placebo controlled trial. Psychopharmacology (Berl) 1996 Jul; 126(1): 50–4CrossRef

Hawley CJ, McPhee S, Quick SJ, et al. A review of the psychomotor effects of paroxetine. Int Clin Psychopharmacol 1997 Jan; 12(1): 13–8PubMedCrossRef

Warrington SJ, Lewis Y. Cardiovascular effects of antidepressants: studies of paroxetine in healthy men and depressed patients. Int Clin Psychopharmacol 1992 Jun; 6Suppl. 4: 59–64PubMedCrossRef

Pollock BG, Laghrissi-Thode F, Wagner WR. Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. J Clin Psychopharmacol 2000; 20(2): 137–40PubMedCrossRef

Musselman DL, Marzec UM, Manatunga A, et al. Platelet reactivity in depressed patients treated with paroxetine: preliminary findings. Arch Gen Psychiatry 2000; 57(9): 875–82PubMedCrossRef

10.

Kaye CM, Haddock RE, Langley PF, et al. A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand 1989; 80 Suppl. 350: 60–75CrossRef

11.

GlaxoSmithKline. Prescribing information for Paxil. 2001

12.

Bayer AJ, Roberts NA, Allen EA, et al. The pharmacokinetics of paroxetine in the elderly. Acta Psychiatr Scand 1989; 80Suppl. 350: 85–6CrossRef

13.

Doyle GD, Laher M, Kelly JG, et al. The pharmacokinetics of paroxetine in renal impairment. Acta Psychiatr Scand 1989; 350 Suppl.: 89–90CrossRef

14.

Krastev Z, Terziivanov D, Vlahov V, et al. The pharmacokinetics of paroxetine in patients with liver cirrhosis. Acta Psychiatr Scand 1989; 350 Suppl.: 91–2CrossRef

15.

Hurst M, Lamb HM. Fluoxetine: a review of its use in anxiety disorders and mixed anxiety depression. CNS Drugs 2000; 14(1): 51–80CrossRef

16.

van Harten J. Overview of the pharmacokinetics of fluvoxamine. Clin Pharmacokinet 1995; 29Suppl. 1: 1–9PubMedCrossRef

17.

Dunbar GC, Claghorn JL, Kiev A, et al. A comparison of paroxetine and placebo in depressed outpatients. Acta Psychiatr Scand 1993 May; 87(5): 302–5PubMedCrossRef

18.

Cohn JB, Crowder JE, Wilcox CS, et al. A placebo- and imipramine-controlled study of paroxetine. Psychopharmacol Bull 1990; 26(2): 185–9PubMed

19.

Cohn JB, Wilcox CS. Paroxetine in major depression: adouble-blind trial with imipramine and placebo. J Clin Psychiatry 1992 Feb; 53Suppl. 2: 52–6PubMed

20.

Dunbar GC, Cohn JB, Fabre LF, et al. A comparison of paroxetine, imipramine and placebo in depressed outpatients. Br J Psychiatry 1991 Sep; 159: 394–8PubMedCrossRef

21.

Fabre LF. A 6-week, double-blind trial of paroxetine, imipramine, and placebo in depressed outpatients. J Clin Psychiatry 1992 Feb; 53(2 Suppl.): 40–3PubMed

22.

Feighner JP, Cohn JB, Fabre Jr LF, et al. A study comparing paroxetine placebo and imipramine in depressed patients. J Affect Disord 1993; 28(2): 71–9PubMedCrossRef

23.

Shrivastava RK, Shrivastava SH, Overweg N, et al. A doubleblind comparison of paroxetine, imipramine, and placebo in major depression. J Clin Psychiatry 1992 Feb; 53 Suppl.: 48–51PubMed

24.

Bignamini A, Rapisarda V. A double-blind multicentre study of paroxetine and amitriptyline in depressed outpatients. Italian Paroxetine Study Group. Int Clin Psychopharmacol 1992 Jun; 6Suppl. 4: 37–41

25.

Christiansen PE, Behnke K, Black CH, et al. Paroxetine and amitriptyline in the treatment of depression in general practice. Acta Psychiatr Scand 1996 Mar; 93(3): 158–63PubMedCrossRef

26.

Freed E, George T, Goldney R, et al. A double-blind multicentre comparison of paroxetine and amitriptyline in Australian general practice. Eur Neuropsychopharmacol 1996 Jun; 6 Suppl. 3: 122CrossRef

27.

Miura S, Koyama T, Asai M, et al. Clinical evaluation of paroxetine HC1, a selective serotonin reuptake inhibitor, in the treatment of depression or depressive episodes: double-blind, parallel group study with amitriptyline HC1 [in Japanese]. J Pharmacol Ther 2000; 28: S187–210

28.

Moller HJ, Berzewski H, Eckmann F, et al. Double-blind multi-center study of paroxetine and amitriptyline in depressed inpatients. Pharmacopsychiatry 1993; 26(3): 75–8PubMedCrossRef

29.

Stuppaeck CH, Geretsegger C, Whitworth AB, et al. A multi-center double-blind trial of paroxetine versus amitriptyline in depressed inpatients. J Clin Psychopharmacol 1994 Aug; 14(4): 241–6PubMedCrossRef

30.

Øhrberg S, Christiansen PE, Severin B, et al. Paroxetine and imipramine in the treatment of depressive patients in psychiatric practice. Acta Psychiatr Scand 1992; 86(6): 437–44PubMedCrossRef

31.

Moon C, Vince M. Treatment of major depression in general practice: a double-blind comparison of paroxetine and lofepramine. Br J Clin Pract Jul 1996; 50(5): 240–4

32.

Chouinard G, Saxena B, Bélanger M-C, et al. A Canadian multi-center, double-blind study of paroxetine and fluoxetine in major depressive disorder. J Affect Disord 1999; 54(1–2): 39–48PubMedCrossRef

33.

De Wilde J, Spiers R, Mertens C, et al. A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients. Acta Psychiatr Scand 1993 Feb; 87(2): 141–5PubMedCrossRef

34.

Fava M, Amsterdam JD, Deltito JA, et al. A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression. Ann Clin Psychiatry 1998; 10(4): 145–50PubMed

35.

Fava M, Rosenbaum JF, Hoog SL, et al. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression. J Affect Disord 2000; 59: 119–26PubMedCrossRef

36.

Gagiano CA. A double blind comparison of paroxetine and fluoxetine in patients with major depression. Br J Clin Res 1993; 4: 145–52

37.

Ontiveros A, Garcia-Barriga C. A double-blind, comparative study of paroxetine and fluoxetine in out-patients with depression. Br J Clin Res 1997; 8: 23–32

38.

Tignol J. A double-blind, randomized, fluoxetine-controlled, multicenter study of paroxetine in the treatment of depression. J Clin Psychopharmacol 1993 Dec; 13(6 Suppl. 2): 18S–22SPubMed

39.

Åberg-Wistedt A, Ågren H, Ekselius L, et al. Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy. J Clin Psychopharmacol 2000 Dec; 20(6): 645–52PubMedCrossRef

40.

Ansseau M, Gabriëls A, Loyens J, et al. Controlled comparison of paroxetine and fluvoxamine in major depression. Hum Psychopharm 1994; 9(5): 329–36CrossRef

41.

Kiev A, Feiger A. A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients. J Clin Psychiatry 1997 Apr; 58(4): 146–52PubMedCrossRef

42.

Szegedi A, Wetzel H, Angersbach D, et al. A double-blind study comparing paroxetine and maprotiline in depressed outpatients. Pharmacopsychiatry 1997 May; 30(3): 97–105PubMedCrossRef

43.

Mertens C, Pintens H. Paroxetine in the treatment of depression: a double-blind multicenter study versus mianserin. Acta Psychiatr Scand 1988 Jun; 77(6): 683–8PubMedCrossRef

44.

Debonnel G, Gobbi G, Turcotte J, et al. Effects of mirtazapine, paroxetine and their combination: a double-blind study in major depression [abstract]. Eur Neuropsychopharmacol 2000; 10(Suppl. 3): 252CrossRef

45.

Baldwin DS, Hawley CJ, Abed RT, et al. A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression. J Clin Psychiatry 1996; 57Suppl. 2: 46–52PubMed

46.

Waintraub L, Septien L, Azoulay P. Efficacy and safety of tianeptine in major depression: evidence from a 3- month controlled clinical trial versus paroxetine [abstract]. Eur Neuropsychopharmacol 2000 Apr; 10Suppl. 2: S51

47.

Tsutsui S. Clinical evaluation of paroxetine HC1, a selective serotonin reuptake inhibitor, in the treatment of depression or depressive episodes: double-blind, parallel group study with trazodone HC1 [in Japanese]. J Pharmacol Ther 2000; 28: S161–85

48.

McPartlin GM, Reynolds A, Anderson C, et al. A comparison of once-daily venlafaxine XR and paroxetine in depressed outpatients treated in general practice. Prim Care Psychiatry 1998; 4(3): 127–32

49.

Montgomery SA, Dunbar G. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacol 1993 Fall; 8(3): 189–95PubMedCrossRef

50.

Claghorn JL, Feighner JP. A double-blind comparison of paroxetine with imipramine in the long-term treatment of depression. J Clin Psychopharmacol 1993 Dec; 13(6 Suppl. 2): 23S–7SPubMed

51.

Hutchinson DR, Vince M. A double blind study in general practice to compare the efficacy and tolerability of paroxetine and amitriptyline in depressed elderly patients. Am J Clin Res 1992; 1: 49–61

52.

Geretsegger C, Stuppaeck CH, Mair M, et al. Multicenter double blind study of paroxetine and amitriptyline in elderly depressed inpatients. Psychopharmacology (Berl) 1995 Jun; 119(3): 277–81CrossRef

53.

Mulsant BH, Pollock BG, Nebes RD, et al. A double-blind randomized comparison of nortriptyline and paroxetine in the treatment of late-life depression: 6-week outcome. J Clin Psychiatry 1999; 60 Suppl. 20: 16–20

54.

Dunner DL, Cohn JB, Walshe III T, et al. Two combined, multi-center double-blind studies of paroxetine and doxepin in geriatric patients with major depression. J Clin Psychiatry 1992; 53 Suppl. 2: 57–60

55.

Guillibert E, Pelicier Y, Archambault JC, et al. A double-blind, multicentre study of paroxetine versus clomipramine in depressed elderly patients. Acta Psychiatr Scand 1989; 80 Suppl. 350: 132–4CrossRef

56.

Schöne W, Ludwig M. A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression. J Clin Psychopharmacol 1993 Dec; 13(6 Suppl. 2): 34S–9SPubMed

57.

Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001; 344: 961–6PubMedCrossRef

58.

Bordet R, Thomas P, Dupuis B. Effect of pindolol on onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double-blind, placebo-controlled trial. Am J Psychiatry 1998; 155(10): 1346–51PubMed

59.

Tome MB, Isaac MT, Harte R, et al. Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. Int Clin Psychopharmacol 1997 Mar; 12(2): 81–9PubMedCrossRef

60.

Bauer M, Zaninelli R, Müller-Oberlinghausen B, et al. Paroxetine and amitriptyline augmentation of lithium in the treatment of major depression: a double-blind study. J Clin Psychopharmacol 1999; 19(2): 164–71PubMedCrossRef

61.

Katona CLE, Hunter BN, Bray J. A double-blind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia. Int J Geriatr Psychiatry 1998; 13(2): 100–8PubMedCrossRef

62.

Pezzella G, Moslinger-Gehmayr R, Contu A. Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline. Breast Cancer Res Treat 2001; 70(1): 1–10PubMedCrossRef

63.

Bird H, Broggini M. Paroxetine versus amitriptyline for treatment of depression associated with rheumatoid arthritis: a randomized, double blind, parallel group study. J Rheumatol 2000; 27: 2791–7PubMed

64.

Elliott AJ, Uldall KK, Bergam K, et al. Randomized, placebocontrolled trial of paroxetine versus imipramine in depressed HIV-positive outpatients. Am J Psychiatry 1998; 155(3): 367–72PubMed

65.

Nelson JC, Kennedy JS, Pollock BG, et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. Am J Psychiatry 1999; 156(7): 1024–8PubMed

66.

Costa e Silva JA, Ruschel S, Caetano D. A randomised, double-blind, controlled study of paroxetine and fluoxetine in the treatment of patients with major depression associated with anxiety [in Portuguese]. Rev Bras Med 1996 Jan 28; 53: 92–6

67.

Ravindran AV, Judge R, Hunter BN, et al. A double-blind, multicenter study in primary care comparing paroxetine and clomipramine in patients with depression and associated anxiety. Paroxetine Study Group. J Clin Psychiatry 1997 Mar; 58(3): 112–8PubMedCrossRef

68.

Lepine JP, Altamura C, Ansseau M, et al. Tianeptine and paroxetine in major depressive disorder, with a special focus on the anxious component in depression: an international, 6-week double-blind study. Hum Psychopharmacol 2001 Apr; 16: 219–27PubMedCrossRef

69.

Williams Jr JW, Barrett J, Oxman T, et al. Treatment of dysthymia and minor depression in primary care: a randomized controlled trial in older adults. JAMA 2000 Sep 27; 284: 1519–26PubMedCrossRef

70.

Barret JE, Williams Jr JW, Oxman TE, et al. Treatment of dysthymia and minor depression in primary care: a randomized trial in patients aged 18 to 59 years. J Fam Pract 2001 May; 50: 405–12

71.

Wheadon DE, Bushneil WD, Steiner M. A fixed dose comparison of 20, 40 or 60 mg paroxetine to placebo in the treatment of obsessive-compulsive disorder [abstract]. Annual Meeting of the American College of Neuropsychopharmacology (ACNP); 1993 Dec; San Juan, Puerto Rico

72.

Zohar J, Judge R. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators. Br J Psychiatry 1996 Oct; 169(4): 468–74

73.

Steiner M, Bushnell WD, Gergel IP, et al. Long-term treatment and prevention of relapse of OCD with paroxetine [abstract no. NR354]. 148th Annual Meeting of the American Psychiatric Association; 1995 May 20–25; Miami (FL), 150

74.

Dunbar G, Steiner M, Bushnell WD, et al. Long-term treatment and prevention of relapse of obsessive compulsive disorder with paroxetine. Eur Neuropsychopharmacol 1995 Sep; 5 (Spec. Iss.): 372CrossRef

75.

Mundo E, Bianchi L, Bellodi L. Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study. J Clin Psychopharmacol 1997 Aug; 17(4): 267–71PubMedCrossRef

76.

Oehrberg S, Christiansen PE, Behnke K, et al. Paroxetine in the treatmentof panic disorder. arandomised, double-blind, placebocontrolled study. Br J Psychiatry 1995 Sep; 167(3): 374–9

77.

Ballenger JC, Wheadon DE, Steiner M, et al. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 1998; 155(1): 36–42PubMed

78.

Bakker A, van Dyck R, Spinhoven P, et al. Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorder. J Clin Psychiatry 1999; 60: 831–8PubMedCrossRef

79.

Lecrubier Y, Bakker A, Dunbar G, et al. A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand 1997 Feb; 95(2): 145–52

80.

Lecrubier Y, Judge R. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Acta Psychiatr Scand 1997; 95(2): 153–60PubMedCrossRef

81.

Perna G, Bertani A, Caldirola D, et al. A comparison of citalopram and paroxetine in the treatment of panic disorder: a randomized, single-blind study. Pharmacopsychiatry 2001 May; 34(3): 85–90PubMedCrossRef

82.

Allgulander C. Paroxetine in social anxiety disorder: a randomized placebo-controlled study. Acta Psychiatr Scand 1999; 100: 193–8PubMedCrossRef

83.

Baldwin D, Bobes J, Stein DJ, et al. Paroxetine in social phobia/ social anxiety disorder. Randomised, double-blind, placebocontrolled study. Paroxetine Study Group. Br J Psychiatry 1999 Aug; 175: 120–6

84.

Lydiard RB, Bobes J. Therapeutic advances: paroxetine for the treatment of social anxiety disorder. Depress Anxiety 2000; 11(3): 99–104PubMedCrossRef

85.

Stein MB, Liebowitz MR, Lydiard RB, et al. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA 1998; 280(8): 708–13PubMedCrossRef

86.

Stein DJ, Berk M, Els C, et al. A double-blind placebo-controlled trial of paroxetine in the management of social phobia (social anxiety disorder) in South Africa. S Afr Med J 1999; 89(4): 402–6PubMed

87.

Kumar R, Pitts C, Carpenter D. Response to paroxetine is maintained during continued treatment in patients with social anxiety disorder [abstract]. Eur Neuropsychopharmacol 1999; 9Suppl. 5: S312–3CrossRef

88.

Hair T, Kumar R, Rolfe TE. Maintained efficacy of paroxetine in the treatment of social anxiety disorder [abstract]. American Psychiatric Association 2000 Annual Meeting. The Doctor-Patient Relationship: New Research Abstracts; 2000 May 13; Chicago, 234-5

89.

Hair T, Castrogiovanni P, Domenech J, et al. Short-term efficacy of paroxetine in social anxiety disorder is maintained after long-term treatment. Int J Neuropsychopharmacol 2000 Jul; 3Suppl. 1: S227

90.

Pollack MH, Zaninelli R, Goddard A, et al. Paroxetine in the treatment of generalized anxiety disorder: results of a placebocontrolled, flexible-dosage trial. J Clin Psychiatry 2001 May; 62(5): 350–7PubMedCrossRef

91.

Bellew KM, McCafferty JP, Iyengar M, et al. Paroxetine for the treatment of generalized anxiety disorder: a double-blind placebo controlled trial [poster]. American Psychiatric Association 2000 Annual Meeting. The Doctor-Patient Relationship: New Research Abstracts; 2000 May 13; Chicago, 1

92.

HewettK, Adams A, Bryson H, et al. Generalised anxiety disorder-efficacy of paroxetine [poster]. World Congress of Biological Psychiatry; 2001 Jul 1–6; Berlin

93.

Rocca P, Fonzo V, Scotta M, et al. Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr Scand 1997; 95(5): 444–50PubMedCrossRef

94.

Stocchi F, Nordera G, Jokinen R, et al. Efficacy and tolerability of paroxetine for long-term treatment of GAD [abstract no. NR633]. American Psychiatric Association 2001 Annual Meeting; 2001 May 5; New Orleans, 384

95.

Marshall RD, Beebe KL, Oldham M, et al. Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. Am J Psychiatry 2001; 158(12): 1982–8PubMedCrossRef

96.

Tucker P, Zaninelli R, Yehuda R, et al. Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 2001; 62(11): 860–8PubMedCrossRef

97.

Pitts CD, Beebe KL, Ruggiero L, et al. Paroxetine efficacy in male and female patients with PTSD. American Psychiatric Association 2001 Annual Meeting; 2001 May 5; New Orleans, 375

98.

Lane RM. A critical review of selective serotonin reuptake inhibitor-related sexual dysfunction: incidence, possible aetiology and implications for management. J Psychopharmacol (Oxf) 1997; 11(1): 72–82CrossRef

99.

Montejo AL, Llorca G, Izquierdo JA, et al. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry 2001; 62 Suppl. 3: 10–21

100.

Montgomery SA. A meta-analysis of the efficacy and tolerability of paroxetine versus tricyclic antidepressants in the treatment of major depression. Int Clin Psychopharmacol 2001; 16: 169–78PubMedCrossRef

101.

SmithKline Beecham Pharmaceuticals. Prescribing information UK: seroxat tablets 20mg, 30mg, liquid 20mg/10ml [online]. Available from URL: http://emc.vhn.net/emc/assets/c/html/displaydoc.asp?documentid=2057 [Accessed 2001 Nov 12]

102.

Centre for Evidence-Based Mental Health. A systematic guide for the management of depression in primary care [online]. Available from URL: http://www.psychiatry.ox.ac.uk/cebmh/guidelines/depression/depression1.html [Accessed 2001 Nov 12]

103.

World Health Organization. Mental disorders in primary care. Geneva: World Health Organization, 1998; WHO/MSA/MNHIEAC/98.1

Title: Spotlight on Paroxetine in Psychiatric Disorders in Adults
Authors: Antona J. Wagstaff
Susan M. Cheer
Anna J. Matheson
Douglas Ormrod
Karen L. Goa
Publication date: 01-06-2002
Publisher: Springer International Publishing
Published in: CNS Drugs / Issue 6/2002
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI: https://doi.org/10.2165/00023210-200216060-00006

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Spotlight on Paroxetine in Psychiatric Disorders in Adults

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2002

SUNCT Syndrome

Differentiation of Multiple Sclerosis Subtypes

Pharmaceutical Company Internet Sites As Sources of Information About Antidepressant Medications

Morphological Brain Changes in Depression

Practical Approaches to Migraine Management